drugset / Trial / NCT00003330
Interleukin-12 in Treating Patients With Advanced Cancer
NaSingle-groupOpen-labelTreatment
Summary
Phase I trial to study the effectiveness of interleukin-12 in treating patients who have advanced cancer. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
Timeline
- Start
- 1998-07
- Primary completion
- 2002-04
- Completion
- —
Publications
- Results Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res. 2000 May;6(5):1678-92.
- Results Gollob JA, Veenstra KG, Mier JW, Atkins MB. Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. J Immunother. 2001 Jan-Feb;24(1):91-8. doi: 10.1097/00002371-200101000-00011.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | interleukin-12 | Protein / enzyme biologic | 30 ng | Intravenous |
| Subject | interleukin-12 | Protein / enzyme biologic | 500 ng | Intravenous |
| Subject | interleukin-12 | Protein / enzyme biologic | 700 ng | Intravenous |